The clinical picture on presentation was dire. Acute severe mitral regurgitation had produced extreme respiratory failure despite maximal ventilatory support: while breathing pure oxygen, the patient’s arterial blood showed a pH of 7.144, a partial pressure of oxygen of only 48 mmHg, and a partial pressure of carbon dioxide of 101 mmHg. Those numbers describe profound, life-threatening hypoxemia and hypercapnia, the biochemical signature of lungs so waterlogged and failing that gas exchange had nearly collapsed. Fulminant pulmonary edema of this kind, driven by the sudden backflow of blood through an incompetent mitral valve, typically leaves clinicians with a narrow and dangerous window in which to act.

The standard emergency answer for such patients is often veno-arterial ECMO, in which blood is drained from the venous system, oxygenated outside the body, and returned to the arterial circulation, simultaneously supporting the heart and lungs. But the authors highlight a well-recognized paradox: VA-ECMO can worsen pulmonary congestion in patients with a failing left ventricle. By returning oxygenated blood to the aorta, it increases the afterload against which the damaged left ventricle must pump, which can push blood backward into the lungs and aggravate the very edema the therapy is meant to buy time against. Recent literature, including a 2024 position paper on dual-circulation physiology during venoarterial ECMO and multicenter data linking left ventricular unloading to lower mortality in cardiogenic shock, has sharpened attention on this problem and on strategies to relieve the loaded ventricle.

The surgical team proceeded with emergency mitral valve replacement under cardiopulmonary bypass. When the operation ended, however, the heart could not be weaned from the bypass machine: severe pulmonary edema and post-cardiotomy shock conspired to keep the ventricle too weak and the lungs too compromised for independent circulation. Rather than defaulting to VA-ECMO, the surgeons made a deliberate split decision. They implanted an Impella 5.5, an axial-flow catheter-mounted pump, directly into the ascending aorta through a prosthetic graft, positioning it across the aortic valve so it could draw blood out of the left ventricle and deliver it antegrade into the systemic circulation. Then they added veno-venous ECMO, which drains deoxygenated blood from the venous side and returns it oxygenated to the veins, supporting only the lungs.

The physiological logic of this combination is what makes the case compelling. The Impella 5.5 provides left ventricular unloading and forward systemic flow, reducing the pressure that would otherwise be transmitted back into the pulmonary vasculature, while VV-ECMO takes over gas exchange without adding any arterial afterload at all. In effect, the circulation and the respiration were decoupled and managed independently, avoiding the differential hypoxemia problem known as harlequin syndrome, in which poorly oxygenated blood ejected by the native heart mixes with oxygenated ECMO return in patients on VA-ECMO. The authors argue that this decoupled strategy may be an effective option for selected patients suffering concomitant severe respiratory and circulatory failure, particularly when VA-ECMO risks compounding pulmonary congestion.

The early postoperative course was rocky but revealing. The patient initially required substantial vasoactive and inotropic drug support to maintain blood pressure, a reflection of both the stunned post-cardiotomy myocardium and the inflammatory burden of prolonged critical illness. Serum lactate, a biochemical marker of inadequate tissue perfusion, peaked transiently at 10.9 mmol/L on postoperative day one, a level indicating significant anaerobic metabolism. Crucially, however, systemic perfusion was maintained throughout, and as the ventricle recovered, the team was able to stabilize the circulation on Impella-mediated antegrade flow alone, without ever converting to VA-ECMO or the hybrid V-AV configuration that many centers would have reached for in a similar situation.

Respiratory recovery followed a parallel and equally instructive trajectory. Under VV-ECMO-supported lung rest, with the membrane lung shouldering the work of oxygenation and carbon dioxide removal, and under an intensive diuretic regimen to strip away the excess lung water, the patient’s respiratory function improved progressively. Bilateral pulmonary opacities on imaging, the radiographic shadow of the edema, gradually cleared. VV-ECMO was removed on postoperative day three, a remarkably short run that suggests the lung injury, while fulminant, was largely hydrostatic and reversible once the circulatory derangement was corrected. The Impella 5.5 was explanted on postoperative day six as ventricular function recovered.

The outcome was a full survival: the patient was discharged on postoperative day 46 without any neurological sequelae, an outcome that would have been considered improbable at the moment of presentation, when his blood gases were incompatible with sustained life on conventional support. For a case report, the message is less about a single heroic save than about a reproducible physiological principle. The authors position the combination as a way to sidestep the afterload penalty of VA-ECMO while still providing both pump function and gas exchange, drawing on established techniques for direct aortic Impella implantation that allow the device to be placed surgically with secure fixation.

The report also underscores how rapidly the mechanical support landscape is evolving. The Impella 5.5, originally developed as a percutaneous left ventricular assist device for high-risk procedures and cardiogenic shock, is increasingly being combined with ECMO in creative configurations, and the literature now includes dedicated analyses of left ventricular decompression during VA-ECMO and reviews of the collision between native and device circulations. This case adds a new entry to that growing repertoire: instead of adding an Impella to unload a ventricle already supported by VA-ECMO, the team used the pump as the sole circulatory engine and paired it with purely respiratory extracorporeal support. The authors are careful to frame the approach as appropriate for selected patients, and a single case cannot establish superiority over conventional strategies. But for clinicians confronting the double failure of heart and lungs, particularly when pulmonary edema makes VA-ECMO counterproductive, the case provides a concrete, technically documented template. It suggests that thinking about circulatory and respiratory failure as separable problems, rather than as a single indication for one device, can turn a nearly certain death into a discharge home with an intact brain.

Subject of Research: Combined veno-venous ECMO and direct aortic Impella 5.5 support for emergency mitral valve replacement in acute severe mitral regurgitation with fulminant pulmonary edema

Article Title: Combined veno-venous ECMO and direct aortic impella 5.5 support enabling emergency mitral valve replacement in acute severe mitral regurgitation with fulminant pulmonary edema

Article References: Combined veno-venous ECMO and direct aortic impella 5.5 support enabling emergency mitral valve replacement in acute severe mitral regurgitation with fulminant pulmonary edema. (n.d.). https://doi.org/10.1007/s10047-026-01592-5

Image Credits: AI Generated

DOI: 10.1007/s10047-026-01592-5

Keywords: veno-venous ECMO, Impella 5.5, mechanical circulatory support, left ventricular unloading, differential hypoxemia, mitral regurgitation, pulmonary edema, cardiogenic shock, mitral valve replacement, cardiac surgery, Journal of Artificial Organs, case report